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Objective: To evaluate the effectiveness of pharmacist-led medication review in chronic pain 
management. 
Methods: Six electronic databases (Medline, Embase, PsycInfo, CINHAL, CENTRAL, 
International Pharmaceutical Abstracts) reference lists of retrieved articles and relevant websites 
were searched for randomised controlled trials (RCTs) published in the English language 
involving adults with chronic pain. Studies were included if one of the intervention arms had 
received pharmacist-led medication review independently or as part of a multidisciplinary 
intervention. Risk of bias was assessed for all the included studies. 
Results: The search strategy yielded 583 unique articles with five RCTs included. Compared to 
control, meta-analysis showed that participants in the intervention group had: a 0.8 point 
reduction in pain intensity on a 0 to 10 numerical rating scale (NRS) at 3-months (95% CI, -1.28 
to - 0.36) and a 0.7 point reduction (95% CI -1.19 to - 0.20) at 6-months; a 4.84 point (95% CI, -
7.38 to -2.29) and -3.82 point (95% CI, -6.49 to -1.14) improvement in physical functioning on a 
0 to 68 point function subscale of  Western Ontario and McMaster Universities Arthritis Index 
(WOMAC) at 3-months and 6-months respectively; and a significant improvement in patient 
satisfaction equivalent to a µVPDOOWRPRGHUDWHHIIHFW.¶  
Discussion:  Pharmacist-led medication review reduces pain intensity and improves physical 
functioning and patient satisfaction. However, the clinical significance of these findings remain 
uncertain due to small effect size and  nature of reported data within clinical trials  which limits 
recommendation of wider clinical role of pharmacist in chronic pain management. 
Keywords: Pharmacist; Medication review; Chronic pain; Systematic review 
  
Introduction 
High prevalence, associated long term morbidity and lack of a permanent cure make chronic pain 
one of the most challenging diseases to manage. In the USA, chronic pain affects more than 100 
million people and the prevalence is higher than for  diabetes, heart diseases and cancer 
combined.1 In Europe, one in every five adults suffers from chronic pain of moderate to severe 
intensity.2  Both prescription and non-prescription analgesics are extensively used in chronic 
pain management but inappropriate and suboptimal use of analgesics has been reported.3  In 
2007, almost 12,000 cases of unintentional drug poisoning involving prescription analgesics4  
were reported and in 2008, almost 15,000 people died due to overdoses of opioid analgesics in 
the USA alone.5  Therefore, the safe and effective use of analgesics is critical to ensure optimum 
analgesia, to prevent adverse effects and drug related problems, and to minimise abuse of 
analgesics.  
Over the past decade, with the increase in the number of nurse and pharmacist prescribers, 
researchers have become interested in evaluating the effectiveness of their extended clinical role 
in the management of different diseases and settings.6-9  For chronic pain, the limited capacity of 
general practioners (GPs) and long waiting times for appointments in secondary care10 present an 
opportunity for healthcare professionals other than GPs to take on key aspects of chronic pain 
management. Studies evaluating the role of the pharmacist in chronic pain have reported mixed 
results.11 A meta-analysis of the effectiveness of pharmacist-led educational interventions for 
chronic pain management showed a statistically significant reduction in pain intensity and 
adverse effects, and an improvement in patient satisfaction in those receiving interventions.11 
However, no benefit was seen in interference from pain on daily life and self-efficacy. 
Furthermore, the reduction in pain intensity was statistically, but not clinically, significant.  
Since no systematic review has yet evaluated the effectiveness of pharmacist-led medication 
review for chronic pain management, the aim of this systematic review was to fill this gap. The 
systematic review was prospectively registered with PROSPRO (Registration number: 
CRD42012001957) and the protocol has been previously published.12  
MATERIALS AND METHODS 
Study Selection 
The following databases were searched between April-June 2012 using a pre-defined search 
strategy.  
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 We searched for randomized controlled trials (RCTs) and non-randomized studies (quasi-
experimental, controlled before-and-after study) having at least one control group Non-
randomized studies were only to be considered for inclusion if fewer than three RCTs were 
eligible for inclusion on searching. Waiting list controls, usual care, attention only and any other 
active control were accepted as appropriate controls. Studies were considered for inclusion if one 
of the intervention arms received either pharmacist-led medication review delivered 
independently, or as part of complex multidisciplinary interventions, where the pharmacist was 
part of the multidisciplinary team. Websites of American, Canadian and Royal (British) 
Pharmaceutical societies were also searched together with the reference lists of the retrieved 
articles to identify additional eligible studies. Where necessary, the corresponding authors of the 
included studies were contacted to obtain additional information and to identify any unpublished 
studies. The full search strategy is available from the corresponding author on request. 
Studies involving chronic pain patients 18 years and older were included regardless of 
participants' gender, type and aetiology of chronic pain. We used The International Association 
for the Study of Pain (IASP) definition of chronic pain: ³3DLQZLWKRXWDSSDUHQWELRORJLFDOYDOXH
WKDW KDV SHUVLVWHG EH\RQG WKH QRUPDO WLVVXH KHDOLQJ WLPH XVXDOO\ WDNHQ WR EH  PRQWKV´.13 
Studies involving patients with malignant or cancer pain were excluded to avoid clinical 
heterogeneity. Studies published in the English language (full text or abstract) were only 
considered. Study titles and abstracts of the studies were screened independently by two authors 
(MAH and DPA). Full texts of all studies considered potentially relevant were retrieved. Finally, 
MAH and DPA independently selected studies meeting the pre-defined inclusion criteria.   
Disagreements were resolved through discussion and if agreement was not reached, a third 
review author (MB) was consulted. 
Assessment of risk of bias and data extraction 
7KHULVNRIELDVZDVDVVHVVHGXVLQJWKH&RFKUDQH&ROODERUDWLRQV¶WRROIRUDVVHVVLQJULVN
of bias by one reviewer (MAH) and verified by another reviewer (SJC) using a standardized 
form.14 This tool is domain-based as opposed to a checklist or scale (see Results for domains). 
For cluster randomized controlled trials, risk of bias was assessed across two additional domains 
including loss of clusters and appropriate statistical analysis. Each domain was assessed and 
categorised into low risk of bias, high risk of bias or unclear risk of bias based on the 
recommendations of Higgins and Green.14 Disagreements were resolved through discussion and 
if consensus was not reached a third reviewer (MB) was consulted. 
Data were extracted by MAH and verified by MB using a standardized data collection 
form.  The data collection form was pilot tested. Disagreements were resolved through 
discussion, and if no consensus was reached, opinion of a third reviewer (SJC) was requested.  
 
Data synthesis 
Review Manager (RevMan 5.1) was used for data analysis. Mean difference (MD) was 
calculated for all continuous variables (e.g. pain intensity) when outcomes were measured using 
the same scale and when different scales were used, standardized mean difference (SMD) was 
calculated with corresponding 95% confidence intervals. Relative risk (RR) with 95% 
confidence intervals was calculated for dichotomous variables. The decision to pool data using 
meta-analysis was based on the clinical homogeneity in terms of the population, intervention, 
outcome measures and timing of outcome measures of all the included studies. Clinical 
homogeneity was determined by discussion among the review authors and clinically 
heterogeneous trials were not combined statistically. Statistical heterogeneity was determined by 
using chi-VTXDUH Ȥ2) and I2 statistic. Statistical heterogeneity determined the choice of using a 
random- or fixed-effects model for meta-DQDO\VLV$Ȥ2 P value of greater than 0.1 and an I2 value 
of less than 50% was used to indicate statistical homogeneity.14 A random-effects model was 
used to combine clinically homogeneous but statistically heterogeneous clinical trials, whereas 
clinical and statistical homogenous trials were combined using the fixed-effects model.  
  
RESULTS 
Characteristics of Included Study  
Six hundred and sixty-four articles were retrieved through database searches (578 after 
de-duplication). Of these 578, 27 were considered relevant after title and abstract screening. An 
additional five articles were found including two each through author contact and reference list 
searching, and one through website searching. Of these 32 articles, nine reports of five studies 
met the inclusion criteria for review.15-23  Figure 1 illustrates the search process and the reasons 
for exclusion.  Two trials were conducted in the UK19-21  and one each in Canada,22 Germany,18 
and the USA.23  
The included studies comprised three individually randomized 19,21,23  and two cluster 
randomized controlled studies 18,22 randomizing 1035 patients in total. All followed up the 
patients for at least 3 months, three for 6 months and one for 12 months. All studies had their 
first follow-up at 3-months except for Hoffman et al18 where follow-up was at 4 months. In total, 
131 patients (12.7%) were lost to the first follow-up. Two trials included patients with chronic 
pain of various aetiologies,21,23 another two involved patients with knee pain associated with 
osteoarthritis 19,22  and one involved chronic headache and migraine patients.18  In four trials 
where gender was reported, the majority of the participants were females (61.8%).18,19,22,23  The 
mean age of participants varied between 62.7 years (S.D.±9.2) in Marra et al study,22 67.9 years 
(S.D.±8.2) in the Hay et al.19  study and 42.70 years (S.D.±13) in the Hoffman et al. study.18  The 
study by Bruhn et al.16,21 did not report age and participants in the Gammaitoni et al.23  study 
ranged from 35-64 years. 
  
Nature and delivery of Intervention 
In three trials18,19,21 the intervention was pharmacist-led medication review alone while in 
the other two 22-23  the intervention involved medication review as part of a multi-component 
intervention (Table 1). In the Marra et al study,22  the intervention also comprised two 
components. First was a face-to-face consultation with a pharmacist who educated patients on 
aspects of osteoarthritis (OA), conducted medication review to ensure safe use of analgesics, 
referred patients to a physiotherapist-guided exercise programme (second component) and 
UHTXHVWHGSDWLHQWV¶SULPDU\FDUHSK\VLFLDQVWRDSSURYHWKHLULQFOXVLRQLQWKHH[HUFLVHSURJUDPPH
Over the 6 months follow-up period, 297 patient-pharmacist consultations generated 255 
comments and recommendations, including 49 medication-UHODWHGUHFRPPHQGDWLRQVWRSDWLHQWV¶
SULPDU\ FDUH SK\VLFLDQ 7KH SKDUPDFLVW DOVR IROORZHG WKH SDWLHQWV¶ SURJUHVV PRQWKO\ IRU VL[
months. The physiotherapist recommended an individualized home exercise programme after a 
one-hour consultation with each patient.  The participants attended an exercise class twice per 
week for six weeks. Participants in the control group received an educational leaflet on knee OA 
developed by the Canadian Arthritis Society. 
In the Gammaitoni et al trial,23  the intervention had two components.  The first was a 
specialised prescription service provided by a palliative care pharmacy company (PainRxperts) 
ZKLFKGHOLYHUHGSDWLHQWV¶PHGLFDWLRQWRWKHLUKRPHRUWRWKHFOLQLF7KHDLPRIWKHVHUYLce was to 
improve accessibility to pain medicine and reduce the burden of managing medication treatment 
IRU FOLQLFDO SUDFWLFH 7KH VHFRQG FRPSRQHQW ZDV SURDFWLYH PRQLWRULQJ RI SDWLHQWV¶ PHGLFDWLRQ
therapy for any potential or actual drug related problem (DRP) by a palliative care trained 
pharmacist to ensure that the drug therapy was achieving an improvement in quality of life. In 
total, 81 phone calls were made by the pharmacist including 45 to patients (mean 1.2 calls per 
patient) and 36 to the clinic staff. Most calls concerned patient monitoring/administration of the 
Brief Pain Inventory (BPI) (n=36),24 questions about medication use (n=22) and delivery of 
medications (n=11). On average, each patient contact lasted 12 minutes, and 9 minutes for clinic 
staff. Fifteen out of 16 recommendations made to the clinic staff were accepted, including: 
addition of an adjuvant (n=4), drug change (n=2), dose change (n=3), frequency change (n=2), or 
dosing conversion (n=5). The control group received usual care as prior to study with the 
exception of filling in questionnaires at baseline and 3 months follow up. 
Hay et al,17,19 used two independent intervention groups: pharmacy review group and 
community physiotherapy group. Data for the pharmacy review group only was extracted  and 
presented in this systematic review. Participants in the pharmacy review group received an 
enhanced pharmacy review plus an education leaflet from an experienced community pharmacist 
LQJHQHUDOSUDFWLFHVXUJHULHVZLWKDFFHVVWRSDWLHQWV¶PHGLFal records. The trial protocol permitted 
three to six sessions of approximately 20 minutes each over 10 week period. The pharmacist 
used a pre-defined set of questions for initial assessment and optimized/changed drug therapy, if 
necessary, based on an algorithm and clinical needs. In total, 335 pharmacist-patient 
consultations took place (mean 3.2 per patient; range 2-5). The mean time spent per patient was 
around 63 minutes in 3 sessions. Participants in the control group received the same education 
leaflet and a telephone call from a rheumatology nurse to reinforce the leaflet advice within 
seven days of randomization. 
 In the Hoffmann et al study,18 the intervention group received an individualized 
counselling session by trained community pharmacists with the aim of optimising 
pharmacotherapy, promoting self-management, goal setting and pacing activities. Each patient 
received approximately two hours of counselling and each pharmacy counselled 4.6 ± 3.06 
patients on average (range 1-15). Participants in the control group continued to receive usual 
pharmaceutical consultations with pharmacists who were not formally trained in headache/pain 
management. 
In the Bruhn et al study,16,20,21 there were two independent intervention groups: 
pharmacist medication review either with recommendations to the GP or pharmacist prescribing. 
Further data on the nature and duration of the intervention were not available. Authors were 
contacted but unable to provide data due to funding restrictions. 
Risk of bias  
Three trials 19,22,23 described adequate methods for random sequence generation (Figure 2). Hay 
et al.19 used a random number generator which allocated to intervention or control groups in pre-
determined sequence blocks of six by general practice.  The study statistician generated values 
from a uniform (0, 1) distribution in the Marra et al study 22 and a computer programme was 
used to randomly assign the names to either the intervention group or the control group in the 
Gammaitoni et al trial.23 However, Gammaitoni et al  did not describe how the selection of 107 
patients from pain clinics was undertaken prior to this random allocation to groups.23 Methods of 
random sequence generation were not adequately explained by Bruhn et al 21 and Hoffman et 
al.18  Only Hay et al.19 described an adequate method of allocation concealment (sequentially 
numbered opaque envelops). Allocation concealment was not possible for the cluster randomized 
trials 18,22  and is not considered an issue.14  
In all the trials, it was impossible to blind pharmacists delivering the intervention and the 
participants receiving it due to nature of intervention. Outcome assessors were blinded in two 
trials only 19,22 and Hoffmann et al 18 who collected data through a computer aided, standardized 
telephone interview but it was not made clear whether people who handled and analysed the data 
were blinded or not. 
All trials 18,19,21,22  except one 23 used the intention to treat principle for analysing their 
data, minimizing attrition bias. There was low risk of selective reporting of an outcome across 
four trials 18,19,22,23 and unclear risk in one of the trials. Although the study protocol was available 
for only one study,22  low risk was assigned to other trials since the authors reported outcomes 
with non-significant P-values as well. 
 
There were no baseline differences between intervention and control groups in any of the 
trials except one. In the Marra et al trials,22  there were significant differences at baseline in pain 
scores measured by the Health Utilities Index-3,25 a generic instrument to measure quality of life, 
between intervention and usual care groups but there were no significant differences in pain 
scores when measured by the Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) pain subscale.26 Furthermore, participants in the intervention group were slightly 
more educated (86% reported more than high school education compared to 79%), belonged to 
higher socioeconomic class (71% reported an income over $50,000 compared to 59%) and were 
of Asian origin (21% compared to 9%) compared with the usual care group. 
Only one patient was lost to follow up in each group in the Marra et al. 22  study and the 
DXWKRUV WRRN ³FOXVWHULQJ´ LQWR FRQVLGHUDWLRQ LQ VDPSOH VL]H FDOFXODWLRQ DQG GDWD DQDO\VLV
However, in the Hoffmann et al cluster randomized trial,18  the authors did not use appropriate 
statistical techniques and did not allow for the clustering effect in sample size calculation and 
data analysis. 
 Outcomes assessment 
Pain intensity 
Pan intensity was reported in the all the trials using different scales. Gammaitoni et al.23 
measured pain intensity on a 0 to 10 numerical rating scale (NRS) where 0 = no pain and 10= 
pain as bad as you can imagine and the Health Background Questionnaire-Initial Patient Visit. 27 
Hay et al.19 reported pain intensity with the NRS and on a 0 to 20 subscale of WOMAC.26 Bruhn 
et al.21 assessed pain intensity using the pain intensity subscale of the chronic pain grade 
questionnaire (CPG), a 7-item questionnaire to measure pain intensity, severity and functional 
disability.28 Marra et al. 22 measured pain intensity on a 0 to 10 pain subscale of WOMAC while 
Hoffman et al. 18 measured it on a 1 to 10 numerical rating scale where 1=no pain and 10=pain as 
bad as you can imagine. Although pain intensity was measured using different scales in 
Gammaitoni et al, 23 Hay et al 19 and Mara et al,22 all the scales ranged from 0 to 10 where 0 = no 
pain and 10 = pain as bad as you can imagine. 
Four studies showed a significant reduction in pain scores at follow-up. 18-22 Although, 
Hay et al.19  reported a statistically significant reduction in pain scores at 3-month follow up 
(p=0.04), they were not significant at 6 (p = 0.3) and 12 months (p=0.5). However, Marra et al.22  
reported a statistically significant reduction at both 3 and 6 month follow ups (both p<0.05). In 
the study by Hoffmann et al,18  WKHUHZDVDVLJQLILFDQWUHGXFWLRQLQµXQWUHDWHG¶SDLQLQWHQVLW\LQ
ERWK LQWHUYHQWLRQ S DQG FRQWURO JURXS S KRZHYHU UHGXFWLRQ LQ µWUHDWHG¶ SDLQ
intensity remained non-significant in both intervention (p=0.52) and control groups (p=0.92) at 
4-month follow up. 
Pain scores were pooled using meta-analysis. The study by Hoffmann et al.18 involved 
patients with chronic headache and migraine so was clinically heterogeneous and not combined 
statistically. The data reported by Bruhn et al.21  was insufficient for meta-analysis. Since pain 
intensity was measured on different scales, the standardized mean difference (SMD) and 
corresponding standard error were calculated for each of the three studies. For the purpose of 
meta-analysis, change in score from baseline rather than final score was used as it is  more 
efficient and powerful, eliminating between-person variability.14  ,I WKH µDGMXVWHG¶ FKDQJH LQ
score derived from regression model accounting for baseline measurements was reported, it was 
preferred over the crude change in score to calculate SMD, as statistically, adjusted scores are 
considered most precise and least biased.14 Meta-analysis was undertaken for 3 and 6 month 
follow-ups. 
Compared with the control group, there was a significant reduction in pain intensity in 
the intervention group with SMD of ± 0.37 (95% confidence interval - 0.58, - 0.16) (Figure 3). 
This corresponds to a 0.83 point reduction on an 11 point NRS (95% confidence interval -1.28, - 
0.36). There was no heterogeneity in the result (I2=0%). Only two studies reported pain intensity 
at 6-months.19,22 Meta-analysis showed a significant reduction in pain intensity in the 
intervention group compared to the control [SMD ± 0.31 (95% CI -0.53, - 0.09)] corresponding 
to a 0.7 point reduction on a 0 to 10 numerical rating scale (95% CI -1.19, - 0.20). There was 
slight heterogeneity in the result (I2=39%) [Chi2=1.64, df=1, p=0.20] which is considered 
statistically non- significant.14  
  
Physical functioning 
Physical functioning was an outcome measure in all the studies. Marra et al.22  and Hay et 
al.19  assessed physical functioning using a 0 to 10 and 0 to 68 physical functioning subscale of 
WOMAC respectively.26  Higher scores on the WOMAC subscale represented worse (limited) 
physical functioning. Hoffmann et al.18 and Bruhn et al.16 used the physical health subscale of 
SF-36 29  and SF-12,30  valid instruments to measure quality of life, respectively to assess 
physical functioning. Gammaitoni et al.23  assessed pain interference with various daily activities 
(general activity, mood, waking, normal work, relationships, sleep and enjoyment of life) as part 
of PhPI, a survey instrument derived from the BPI24  and the Health Background Questionnaire-
Initial Patient Visit.27  But instead of reporting a recommended summary score calculated from 
these seven interference items,24  the authors reported each item individually.  
Marra et al.22 reported a statistically significant improvement in physical functioning at 3-
months [-0.65; 95% CI (-1.20 to -0.10)] and 6-months [-0.84; 95% CI (-1.45 to -0.24)] in the 
intervention group compared to the control. Hay et al.19 reported a non-significant improvement 
in functioning at 3 months [-2.12; 95%CI (-0.5 to 4.8)], 6 months [-0.96; 95% CI (-4.0 to 2.1)] 
and 12 months [-0.39; 95% CI (-3.8 to 3.0)] in the intervention group. Compared with the control 
group, Gammaitoni et al.23 reported non-significant improvement in pain interference with mood 
(p=0.07), general activity (p=0.37), walking (p=0.92), work (p=1.00), relationships (p=0.72), 
sleep (p=0.62) and enjoyment of life (p=0.76) at 3-months follow up. Similarly, Hoffmann et 
al.18 reported a non-significant improvement in physical health (p=0.85) at the end of the 4-
month study period. Bruhn et al.21 also reported a non-significant improvement in physical health 
(p=0.75) at 6-months follow-up.  
Data were pooled using meta-analysis for three studies excluding Hoffman et al.18  for 
clinical heterogeneity and Bruhn et al.16  for insufficient data. Meta-analysis was undertaken at 3 
and 6 months follow-up.  At 3-months follow up there was a statistically significant 
improvement in the intervention group with SMD of -0.38 (95% CI -0.58, -0.18) compared to the 
control group (Figure 4). This effect is equivalent to 4.84 points (95% CI -7.38, -2.29) on a 0 to 
68 point function subscale of WOMAC.26 There was no heterogeneity in the result (I2=0%). Two 
trials reported physical functioning status at 6-months.19,22 Meta-analysis showed a significant 
improvement in physical functioning at 6-months follow up as well in the intervention group 
compared to the control group with SMD -0.30 (95% CI -0.51,- 0.09) corresponding to -3.82 
points (95% CI -6.49, -1.14) on WOMAC 0 to 68 function subscale.26 There was non-significant 
heterogeneity in the result (I2=33%). 
Patient satisfaction 
Three studies reported patient satisfaction as an outcome.16,19,23 Gammaitoni et al23   
assessed patient satisfaction with different components of the service using the Treatment 
Helpfulness Questionnaire (THQ), a validated measure to assess patient satisfaction with chronic 
pain management service.31  It was modified to include measures of satisfaction with the 
pharmaceutical care programme, including: access to medication, pharmacy service, delivery of 
medication, pharmacist phone calls, time spent obtaining medications, pharmacist medication 
counselling and information provided by the pharmacist. Each item was ranked on a 11 point 
scale ranging from -5 (extremely harmful) to +5 (extremely helpful). Hay et al19 assessed 
satisfaction as a dichotomous outcome (satisfied, not satisfied). For Bruhn et al,16,21  patient 
satisfaction was reported in another linked abstract by Bond et al.20 Patient satisfaction was 
assessed at the end of 3-months using Likert scale ratings of statements about their pain and 
pharmacist consultation, and open ended questions about pharmacist consultations.20  
In the Gammaitoni et al study,23 patients in the intervention group were significantly 
more satisfied with various components of the pharmaceutical care programme including 
pharmacy service (p=0.001), delivery of medication (p=0.001), pharmacist phone calls 
(p=0.003), time spent in obtaining medications (p<0.001), pharmacist medication counselling 
(p=0.003), and information provided by the pharmacist (p=0.013). However, there was no 
significant difference in satisfaction with the whole programme domain (p=0.72) of the patient 
satisfaction survey.  In the control group, patients were only satisfied with psychological 
assessment and treatment (p<0.05). It should be noted here that Gammaitoni et al23 only 
compared the difference in patient satisfaction from baseline to 3-month study period in both 
intervention and control groups independently, but did not compare control with the intervention 
group. In the Hay et al study,19 intervention group patients were significantly more satisfied  with 
treatment at 3-months [-20%; 95% CI (-33 to -6)] and 12-months-[-19%; 95%CI (-32 to -4)] 
follow-up but not at 6-months [-14%; 95%CI (-28 to 1)]. Bond et al,20 linked to Bruhn et al,16,21 
reported that 85% (38/46) of the patients in the prescribing arm were totally satisfied with the 
received treatment. Patient satisfaction rates were not reported for the other intervention 
(medication review alone) and control groups. 
Data for patient satisfaction were pooled for two studies (Figure 5).19,23 Meta-analysis 
showed significantly greater patient satisfaction in the intervention group with SMD -0.39 [95% 
CI (-0.68, -@ 8VLQJ WKH XQLYHUVDO UXOH RI WKXPE WKLV HIIHFW VL]H FRUUHVSRQGV WR µVPDOO WR
PRGHUDWHHIIHFW¶.14,32  
3.4.4.4. Quality of Life: 
Three studies assessed quality of life (QoL).16,18,22 Hoffmann et al18  used the Medical Outcomes 
General Health Survey (SF-36), a 36-item generic tool with demonstrated validity and reliability 
to assess QoL.29 Bruhn et al 21 used the SF-12,30 a validated shorter version of SF-36.29 Marra et 
al22 assessed QoL using WOMAC (global) and Health Utilities Index-3 (HUI-3), a generic and 
preference-scored instrument for measuring health status and health related quality of life.27 
Higher scores on HUI-3 indicate better health.27 
In the Hoffmann et al trial,18 compared to the control group, there was no significant 
difference in the intervention group in the physical health subscale  (p=0.85) of SF-36 but a 
statistically significant difference was found in the mental health subscale (p=0.02) of SF-36 at 
the end of the 4-month study period.  Similarly, Bruhn et al 21 reported a significant improvement 
in the mental health component of SF-12 (p=0.04) but not on the physical health component 
(p=0.75) at 6-months follow-up.  Marra et al 22 reported a significant improvement in WOMAC 
(Global) at 3-months [-1.99; 95% CI (-3.45, -0.54)] and 6-months [-2.40; 95% CI (-4.10,-0.71)] 
in the intervention group compared to the control. However, HUI-3 failed to show significant 
differences in QoL between the intervention and control group at 3-months [0.04; 95% CI (-0.03, 
0.12)] and 6-months [0.01; 95%CI (- 0.06, 0.10)]. 
Meta-analysis was not undertaken as clinical heterogeneity ruled out Hoffmann et al18 
from meta-analysis and insufficient data ruled out trial by Bruhn et al. 16,21  
3.4.4.5. Adverse effects 
Surprisingly, none of the studies except Phelan et al,17  linked to the Hay et al trial,19 
reported adverse effects.  Phelan et al17 reported adverse effects in 30 patients including 
constipation (10), drowsiness (8), gastro intestinal upset (8) and others (4) from prescribed 
analgesics at the initial consultation.  During follow-up the side effects were reduced or stopped 
in 25 patients by amending their medication. The remaining five patients continued with their 
medication unchanged as the medications were effective and the side effects were tolerable.   
Discussion: 
Main results 
7KH VHDUFK VWUDWHJ\ LGHQWLILHG ILYH VWXGLHV ZKLFK PHW WKH LQFOXVLRQ FULWHULD 7KH µJUH\
OLWHUDWXUH¶ZDVQRWVHDUFKHGDQGRQO\VWXGLHVSXEOLVKHGLQWKH(QJlish language were included in 
the systematic review. Pharmacists delivered interventions in different settings such as 
community pharmacies, 18,22  general practices 19,21 and university pain clinic23  indicating that 
the intervention can be potentially delivered in multiple settings. Furthermore, the included trials 
involved patients with various chronic pain aetiologies, demonstrating that the pharmacist-led 
medication review may be effective for all different types of chronic pain conditions. Two trials 
originated from the UK 19,21  and one each from the USA,23  Canada22 and Germany 18 indicating 
a growing interest in evaluating the role of pharmacists in chronic pain management in the 
developed world. This may be due to the high disease burden of chronic pain and a growing 
necessity to involve other healthcare professionals such as pharmacists and nurses actively in 
direct patient care to reduce the workload on general practitioners (GPs)/primary care physicians 
(PCPs) in these countries.  
The risk of bias was assessed for all of the included studies. There was low or unclear 
risk of bias across all the domains except for blinding of participants and personnel where there 
was high risk of bias across all trials. The nature of the intervention, made it impossible to blind 
the pharmacists conducting medication reviews and the patients receiving it as, in most 
instances, the medication review was conducted face-to-face. Although the nature of intervention 
prevented blinding of participants and personnel, outcome assessors were blinded in two of three 
trials used in the meta-analysis, and in the third trial the outcome assessments were carried out 
using a standardized computer aided interview, minimising detection bias. The research evidence 
suggests that, on average, lack of blinding in RCTs is associated with a 9% increment in the 
intervention effect when measured as odds ratio.33   Trials with more subjective outcomes, such 
as pain trials, are likely to be affected more than those which measure objective outcomes.34 
Concealment of allocation is necessary to limit selection bias but allocation concealment may not 
be possible for cluster-randomized controlled trials. Among the included trials, only one study 19 
described an adequate method for concealment of allocation (opaque envelopes). However, 
treatment allocation was disclosed to study nurses by 15 of 325 participants (4.6%).19  
Clinical homogeneity was considered before pooling data statistically. Data from a study 
by Hoffmann et al 18 were not considered for meta-analysis as the study involved patients with 
chronic headache and migraine, which is a neurological condition and has an episodic nature 35 
unlike other chronic pain conditions and requires different treatment. The full report of Bruhn et 
al 21 study has not yet been published and the data reported in conference abstracts 16,20,21 was not 
enough to be pooled statistically. The corresponding author was contacted to obtain additional 
data but had to decline due to restrictions by the funding agency.  It would be interesting to re-
analyse the data once the results of Bruhn et al are available. Other trials were relatively similar 
in terms of nature of intervention, patient follow-XSDQGSDWLHQWV¶SDLQVFRUHV0HWD-analysis was 
conducted at two time points; 3-months and 6-months because the studies included in the 
systematic review reported follow-up results ranging from 3-months to 12-months. Combining 
short with long term trials is not recommended as it produces larger treatment effect than 
combining longer term trials alone.36   Furthermore, the response to placebo tends to be larger in 
longer trials.37 Therefore, meta-analysis was conducted at two time points to limit any bias 
arising from combining short-term trials with long-term trials.  
Since the trials measured the same outcomes using different scales, data were pooled 
using SMD for each outcome. To inWHUSUHW60'LQOLQHZLWKWKH&RFKUDQH¶VJXLGDQFH,14  it was 
re-expressed in the units of a specific measurement scale for two of the three outcome measures 
that were statistically combined, pain intensity and physical functioning. This was achieved by 
multiplying SMDs for pain intensity and physical functioning with the standard deviation of the 
numerical rating scale (0 to 10) and physical functioning subscale of WOMAC (0-20) 
respectively. Both of the standard deviations were obtained as pooled standard deviations of 
baseline scores from the Hay et al study.19 Only the summary measure of effect was back-
transformed to enhance clinical interpretation. For the third outcome measure, patient 
satisfaction, SMD was re-expressed using rules of thumbs for effect sizes 14,31  as one of the 
trials19 measuring patient satisfaction reported it as dichotomous outcome measure and the other 
trial 23  used a modified version of a validated questionnaire, compromising its validity and 
reliability .  
Meta-analysis showed a statistically significant reduction in pain intensity and significant 
improvement in physical functioning in the intervention group compared with the control group. 
However, the clinical significance of these findings is arguable and needs careful consideration. 
The use of average results of continuous data (e.g. pain intensity) can be misleading 38  as it is 
DUJXHGWKDWWKHSRSXODWLRQGLVWULEXWLRQVRISDLQVFRUHVDQGRUSDLQUHOLHIDUHXVXDOO\µ8-VKDSHG¶
(rather than being normally distributed) therefore patients tend to have either very good or very 
poor pain relief. Pain scores/pain relief should therefore be reported as percentage of patients 
responding to the treatment instead of average pain scores, to reflect the actual number improved 
or deteriorated. All the trials included in the systematic review reported mean pain score rather 
than reporting percentages of patients responding to the treatment. The meta-analysis indicates 
potential benefit for patients; however, there is uncertainty around the clinical significance of this 
benefit, limiting wider clinical implementation. Furthermore, medication review was conducted 
as part of multi-FRPSRQHQWLQWHUYHQWLRQVLQWKUHHRIWKHILYHVWXGLHVVRWKH³DFWLYHLQJUHGLHQW´RI
the intervention is not known. However, the impact of the intervention on other drug-related 
outcomes such as: reduction in side effects documented by Phelan et al, 17 in a report linked to 
Hay et al;19 the reduction in the use of Non Steroidal Anti Inflammatory Drugs (NSAIDS) 
documented in Hay et al; 19  DQGWKHKLJKDFFHSWDQFHRISKDUPDFLVWV¶UHFRPPendations suggest 
that pharmacist-led medication review is an important component in overall pain management 
and can improve patient reported outcomes.18,22,23  
 
Implications for pharmacy practice and policy 
With the advance of the concept of pharmaceutical care,39  the focus of pharmacist-led 
services has shifted from being product-centred to patient-centred. This systematic review has 
identified and synthesised data which demonstrates the effectiveness of pharmacist-led 
medication review in chronic pain management. Findings have raised two questions which need 
to be considered by service commissioners and policy makers before a wider role for pharmacists 
in chronic pain management is put into practice. Firstly, certain issues related to delivery of the 
intervention VXFK DV µKRZ PXFK¶ KRZ RIWHQ¶ µKRZ ORQJ¶ PXVW EH FDUHIXOO\ FRQVLGHUHG DV
limited exposure to the service may not be adequate to achieve desired outcomes and prolonged 
use of the service may not be cost-effective and may put an additional burden on healthcare 
systems. Furthermore, it is still unknown whether the pharmacist-led medication review benefits 
all types of chronic pain patients or only certain types of patients. However, it can be argued that 
medication review by an expert pharmacist may reduce drug- related problems and adverse 
effects in all patients irrespective of the pain aetiology. Secondly, short-
courses/programs/residency-training are needed to provide specialised education and training in 
pain management to all the pharmacists in order to achieve maximum clinical benefit. In the 
past, the need for specialised training programmes has also been advocated in the literature.40  
However, to date, such training programmes are not widely available for pharmacists especially 
outside the USA.41,42  Training programmes to produce skilled pharmacy human recourse in pain 
management is essential to ensure sustainability and clinical effectiveness of pharmacist-led pain 
management service.  
The findings of the systematic review may not be transferable to developing countries as 
WKHSKDUPDF\SURIHVVLRQLV LQWUDQVLWLRQIURPµLQGXVWU\-RULHQWHG¶WRµSDWLHQW-RULHQWHG¶2YHUWKH
past decade, changes in undergraduate curriculum have been made together with the 
development of clinical oriented postgraduate programs 43 to equip pharmacists with necessary 
clinical knowledge to meet growing needs of the patients.44,45  However, there is still a long way 
to go before these changes can make significant impact in transforming pharmacy practice and 
relevant polices in these countries. 
Implications for future research: 
The role of pharmacists in chronic pain management is still relatively new and requires 
further exploration. The current evidence suggests that pharmacist-led medication review is 
effective in reducing pain intensity, medication-related adverse effects and improve physical 
functioning. Future research should evaluate the optimum and cost-effective mode/method and 
duration of delivery of the intervention to achieve maximum clinical benefit. Standardization of 
the intervention may not be possible due to the individualized needs of the patients especially 
those taking opioid analgesics may need a more frequent medication review to limit abuse and 
ensure safety.   
Improved quality of reporting of clinical trials involving chronic pain patients is needed. 
In addition to CONSORT guidance  on the conduct and reporting of clinical trials,45  the  
researchers should also adhere to the Initiative on Methods, Measurement, and Pain Assessment 
in Clinical Trials (IMMPACT) guidance  in designing, conducting and reporting their 
findings.36,47,48 As discussed earlier, the researchers instead of reporting average pain scores only 
should always report percentages of patients achieving minimally important, moderately 
important and substantial clinical difference.49  
Trials involving only non-malignant pain patients were included as cancer pain would 
have introduced clinical heterogeneity and complicated clinical interpretation of the findings.  It 
would be interesting to evaluate the effectiveness of pharmacist-led medication review among 
patients with cancer pain as effective management of cancer pain is very important in overall 
cancer management, especially in end of life care. Finally, the cost-effectiveness of pharmacist-
led medication review in chronic pain management is yet to be evaluated and this needs 
addressing.  
The high prevalence of chronic pain and its associated burden on healthcare systems and 
societies across the globe calls for high quality research to improve both diagnosis and 
management of chronic. Unfortunately, research into chronic pain is not well funded.50   In 2008, 
in the USA, less than one percent of National Institutes of Health (NIH) budget was given for 
pain research.51 Underfunding of pain research is likely to damage initiatives to improve pain 
management due to a lack of research evidence. 
Limitations 
In terms of the design of the systematic review there were two major limitations. Firstly, only 
studies reported in English were included, which may have led to language bias.52 Non-English 
studies were not included because the review team had no funding for professional translators. 
One study 53 was excluded during screening of full-texts of included studies as it was published 
in Spanish. However, conflicting results have been reported in the literature examining the extent 
of the effect of language bias on the findings of systematic reviews.54,55 Secondly, publication 
bias may have been introduced as no attempt was made to locate unpublished trials (grey 
literature).  The findings of the research evaluating the impact of LQFOXVLRQRUH[FOXVLRQRIµJUH\¶
literature in meta-analysis of RCTs are inconsistent.56,57  The major issue with data acquisition is 
that only investigators with positive results may be willing to share their results which may 
introduce bias in to the systematic review. Finally, the located studies may only be a small part 
DQGµXQUHSUHVHQWDWLYH¶RIDOOWKHXQSXEOLVKHGVWXGLHV.14  Systematic review authors in future may 
consider including studies not published in English as well as unpublished studies, to overcome 
the above mentioned limitations. 
Conclusion 
Pharmacists can play an important role in improving chronic pain management. They can deliver 
interventions independently and as part of multidisciplinary teams in both community and 
hospital settings. The present systematic review suggests that pharmacist-led medication review 
is effective in reducing pain intensity and improving physical functioning. Furthermore, patients 
were generally satisfied with the service provided by the pharmacists. There is also weak 
evidence of preventing/stopping adverse effects associated with the use of medicines among 
chronic pain patients. The clinical significance of these findings remains to be established. 
Future clinical trials evaluating the effectiveness of pharmacist-led interventions in chronic pain 
must adhere to IMMPACT guidance 47,48  in designing, conducting and reporting their findings 
in addition to CONSORT guidance.46  This will ensure selection of the recommended uniform 
outcome domains and measures, and quality reporting of the trial results facilitating not only 
clinical interpretation but also data synthesis in future.  As the focus of care shifts from hospital 
to community, pharmacists especially community pharmacists have the potential to reduce the 
chronic pain burden on healthcare system and society by ensuring the safe and effective use of 
medicines. 
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Figure 4: Meta-analysis of physical functioning at 3 and 6 month. CI= Confidence Interval, SMD = Standardized mean difference 
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Figure 5: Meta-analysis of patient satisfaction at 3 month. CI= Confidence Interval, SMD = Standardized mean difference 
Table 1: Characteristics of included studies 
Study/Year 
country 
Trial 
design 
Setting Chronic  
pain 
Aetiology 
Sample recruited 
(completed) 
Follow 
up 
(months) 
Intervention    Dose of intervention Pharmacist  
trained in  
pain 
management 
          
Gammaitoni 
et al/ 
2000  
(USA) 
I-RCT University  
pain clinic 
Multiple N=74 
I=38 (20) 
C=36(21) 
3 MR through 
telephone 
interviews, and a 
specialized 
prescription 
delivery service 
81 phone calls (45 to 
patients and 36 to clinic 
staff managing patients) 
were made in 12 weeks. 
Mean 1.2 calls per 
patient. 
Yes 
Hay et 
al/2006 
(UK) 
I-RCT General 
practice 
Knee 
pain 
N=325* 
I=108(100,103,99) 
C=108(92,98,90) 
3, 6 and 
12 
MR and advised 
patients face-to-
face individually 
based on leaflet 
3 to 6 sessions of 20min 
each over 10 weeks 
Not known 
Hoffmann 
et al/2008 
(Germany) 
C-
RCT 
Community 
pharmacy 
Headache 
& 
migraine 
N=410 
I=201 (163) 
C=209 (194) 
4  Face-to-face MR 
plus advice on 
pacing activities 
and goal setting. 
Each pharmacy 
counselled on average 
4.6±3.01 patients (range 
1-15) corresponding to 
Yes 
2hrs/per patient 
approximately 
 
Bruhn et 
al/2011 
(UK) 
I-RCT General 
practice 
Multiple N=196* 
I=70(60,58) 
I**=63(50, 49) 
C=63(54,55) 
3 and 6 MR plus 
recommendations 
to the GP  
Data not available 
 
 
 
Yes 
Marra et 
al/2012 
Canada 
C-
RCT 
Community 
pharmacy 
Knee 
pain 
N=139 
I=73(72) 
C=66(65) 
3 and 6 MR + education+ 
Physiotherapist 
guided exercise 
297 pharmacist-patient 
follow ups  were 
performed over 6 months 
resulting in 355 
recommendations to 
SDWLHQWV¶SULPDU\FDUH
physicians (4.8 
recommendations/patient)  
Yes 
*Two intervention groups in trial. ** The second intervention group also received medication review as part of intervention. Data for 
only one intervention group is presented here. I-RCT=Individual Randomized controlled trial, C-RCT= Cluster randomized controlled 
trial, MR= Medication review, GP=General Practitioner, I=Intervention group, C=Control group, 
  
